These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. New developments in the treatment of patients with multiple myeloma. Minnema MC, van der Spek E, van de Donk NW, Lokhorst HM. Neth J Med; 2010 Jan; 68(1):24-32. PubMed ID: 20103818 [Abstract] [Full Text] [Related]
3. Advances in therapy of multiple myeloma. Bladé J, Rosiñol L. Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053 [Abstract] [Full Text] [Related]
4. Lenalidomide and its role in the management of multiple myeloma. Falco P, Cavallo F, Larocca A, Liberati AM, Musto P, Boccadoro M, Palumbo A. Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796 [Abstract] [Full Text] [Related]
7. Treatment of multiple myeloma: an emphasis on new developments. Kyle RA, Vincent Rajkumar S. Ann Med; 2006 Jun; 38(2):111-5. PubMed ID: 16581696 [Abstract] [Full Text] [Related]
8. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, Crippa C, Ciccone G, Omedè P, Ambrosini MT, Gay F, Bringhen S, Musto P, Foà R, Knight R, Zeldis JB, Boccadoro M, Petrucci MT, GIMEMA--Italian Multiple Myeloma Network. J Clin Oncol; 2007 Oct 01; 25(28):4459-65. PubMed ID: 17785703 [Abstract] [Full Text] [Related]
9. [High-dose melphalan in patients with multiple myeloma]. Moreau P, Le Bonniec M, Harousseau JL. Bull Cancer; 1999 Mar 01; 86(3):283-8. PubMed ID: 10210762 [Abstract] [Full Text] [Related]
13. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. Kaiser M, Lamottke B, Mieth M, Jensen MR, Quadt C, Garcia-Echeverria C, Atadja P, Heider U, von Metzler I, Türkmen S, Sezer O. Eur J Haematol; 2010 Apr 01; 84(4):337-44. PubMed ID: 20028416 [Abstract] [Full Text] [Related]